Natural Killer Cells in Psoriasis

Identification of Cellular Pathways of "Type 1," Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis

(2014) A. S. Haider et al.   JOURNAL OF IMMUNOLOGY

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1

(2010) Amy Strange et al.   NATURE GENETICS

Upregulation of Fas and downregulation of CD94/NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis

(2009) S.W. Son et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis and streptococci: the natural selection of psoriasis revisited

(2009) J.P. McFadden et al.   BRITISH JOURNAL OF DERMATOLOGY

Key Role of Macrophages in the Pathogenesis of CD18 Hypomorphic Murine Model of Psoriasis

(2009) Honglin Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

(2009) Rajan P Nair et al.   NATURE GENETICS

Interferon-α and viral triggers promote functional maturation of human monocyte-derived dendritic cells

(2008) A. Farkas et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

(2008) J. Schmitt et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

(2008) A.K. Brimhall et al.   BRITISH JOURNAL OF DERMATOLOGY

NK cells interactions with dendritic cells shape innate and adaptive immunity

(2008) Fabienne Brilot   Frontiers in Bioscience-Landmark

Activation of Keratinocyte Protein Kinase Cζ in Psoriasis Plaques

(2008) Yuming Zhao et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

A study of the killer cell immunoglobulin-like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris

(2008) M. Jobim et al.   TISSUE ANTIGENS